Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAT-354 for uncontrolled asthma
ACTRN12607000444482Phase 2Terminated
- Sponsor
- Cambridge Antibody Technology
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of tralokinumab in asthma (4 arms), sponsored by Cambridge Antibody Technology. Primary endpoint: Effect of CAT-354 on airway hyperresponsiveness in uncontrolled asthma. Started Sep 2007; status: terminated.
02
Drugs
tralokinumab
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12607000444482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000444482.